1. Home
  2. PTY vs NRIX Comparison

PTY vs NRIX Comparison

Compare PTY & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Corporate & Income Opportunity Fund

PTY

Pimco Corporate & Income Opportunity Fund

HOLD

Current Price

$11.69

Market Cap

2.6B

Sector

Finance

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$23.38

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTY
NRIX
Founded
N/A
2009
Country
United States
United States
Employees
N/A
357
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.5B
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
PTY
NRIX
Price
$11.69
$23.38
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$30.50
AVG Volume (30 Days)
1.0M
1.6M
Earning Date
01-01-0001
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,987,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$48.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
99.31
52 Week Low
$11.58
$8.20
52 Week High
$14.69
$25.09

Technical Indicators

Market Signals
Indicator
PTY
NRIX
Relative Strength Index (RSI) 38.30 58.98
Support Level $11.62 $14.63
Resistance Level $11.98 $24.98
Average True Range (ATR) 0.09 1.21
MACD -0.04 -0.26
Stochastic Oscillator 18.18 52.40

Price Performance

Historical Comparison
PTY
NRIX

About PTY Pimco Corporate & Income Opportunity Fund

PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: